归创通桥-B中期报告 2023

中 期 報 告 2452240414244454677 22 1811 2 1811 2 3485 96827 128 H 9984 1617 H02190 168 www.zyloxmedical.comwww.zyloxtb.com 195 998 839 I. (1)2020(AIS)-(EVT)AIS-EVTAIS-EVT10%AIS50%AIS-EVT300,00020195.4%0.2%(2)20186031,20020235 23(3)DRG 2023 230.1202250.7%72.1%27.9% 202248.7%(i)®PTA(Rx)®®CRD(ii) 202255.9%UltraFree®PTA(UltraFree®DCB)PTAPTA 2820236 30313,300 1. ®20209®(AIS)(TFA)®20232®Plus(TRA)TRA®Plus TRATRA20227R-DASSimmonsTRA202210R-DAS®20% (DRG) 28CE20236 301114 202221202319202310% 3. 20236.22022128.7%202363019OEM2023(LINNC PARIS 2023)2023(LINC 2023) 70% 5728 15202513 ®(CRD)(BGC)BADDASSBADDASSBAlloon guide with large bore Distalaccess catheter with Dual Aspiration with Stent-retriever as Standard approach ®®CRD BADDASS®CRD ® 20212022CEFDA 510K 2023 CE 1313202511 12 UltraFree®PTA(UltraFree®DCB) UltraFree®DCB202011202010CE2021UltraFree®DCB UltraFree®DCB PTA 2023 UltraFree®DCB UltraFree®DCBUltraFree®DCBUltraFree®DCB UltraFree®DCB ePTFE20232027 300mm0.5–1.5mm2023 (ZYLOX Octoplus®) (VV)2019VV399.428.5%2030476.66F51202020228 (ZYLOX Octoplus®) ZYLOX Octoplus®ZYLOX Octoplus®(PE)(DVT)ZYLOX Octoplus®202212 2023CEMDR2024 5F29F II. 230.1202250.7%72.1%27.9% 202248.7%(i)®PTA(Rx)®(®CRD)(ii) 202255.9%UltraFree®PTA(UltraFree®DCB)PTAPTA 59.520226 3037.359.6%(i)20226 30(ii) 20226 30115.547.8%170.620226 3075.6%74.2%(i)(ii) 130.820226 3094.039.1%(i)20226 3021.749.1(ii)20226 3048.355.6 74.920226 3053.340.5%20226 3034.9%32.6%(i)(ii) 50.420226 3049.3202232.3%21.9% 0.620226 300.450.1% 5.220226 304.128.3% 6.820226 3016.258.2% 38.920226 3035.98.5%2023 0.320226 30 (1)H 20236 301,306.9202212 311,205.38.4%20236301,133.6202212 311,334.220236 30153.4202212 31153.6202212 312,693.120236 302,593.8 20236 309.0202212 31 20236 3039.09.0123.05% 20236 300.63%202212 310.45%39.7% 20236 301,696.1202212 311,910.511.2% 20236 30 20236 30114.5 20236 30 20236 30 20236 3070720226 30594 20236 30111.129.7620236 30 III. 57 DRG C.2.1C.2.1 20236 3020236 30 3.10(2)3.2120236 30 2410 2,477.42,063.620217 28347.3289.7 20236 3013.51B(1) 1818 18 20236 30XVXV78352 (1)7,781,25720236 30324,619,744HL (2)WEA Enterprises, LLCWEA2021121II 20236 309,136,780H1,015,1985,114,645H568,2949,862,718H1,095,8578,619,386H957,709 (3)Highlight Medical LimitedHighlight MedicalOurea Biotech HK LimitedOurea BiotechFive Investment LimitedFive InvestmentHomehealth Investment LimitedHomehealth20213 11IIIIFive InvestmentFive InvestmentHighlight Medical HomehealthHighLightCapital Partners I L.P.HighLight Capital Partners I L.P.HighLight Capital GP I Company LimitedHighLight Capital Partners I L.P.HighLight Capital GP I Company LimitedFive InvestmentHighlight MedicalHomehealthOurea BiotechHL Partners II L.P.HL Partners II L.P.HL GP II Company LimitedHL GP II Company LimitedHL PartnersII L.P.HL GP II Company LimitedOurea Biotech (4)36.36%51.54%9,136,780H1,015,1985,114,645H568,294 (5)(i)4,144,199(ii)1,053,004 (6)239,427 (7)167,599 (8)179,571 (9)71,828 20236 30XVXV78352 20236 30XVXV23336 (1)7,781,25720236 30324,619,744HL(2)IIWEA(3)WEA 100%WEA13,476,617HWEA13,476,617H(4)239,427(5)IIIIFiveInvestmentFive InvestmentHighlight MedicalHomehealthHighLight Capital Partners I L.P.HighLight Capital Partners I L.P.HighLight Capital GP I Company LimitedHighLight Capital Partners I L.P.HighLightCapital GP I Company LimitedFive InvestmentHighlight Medical HomehealthOurea BiotechHL Partners II L.P.HL Partners II L.P.HL GP II Company LimitedHL GP II CompanyLimitedHL Partners II L.P.HL GP II Company LimitedOurea Biotech(6)OAPIV(HK)LimitedOAPOrbiMedAsia Partners IV,L.P.OrbiMedAsia GP IV,L.P.OrbiMed Asia GP IV, L.P.OrbiMed Advisors IV LimitedOrbiMed Advisors IV LimitedSunny SharmaSven H. BorhoWilliam Carter Neild Jonathan T. Silverstein Carl L. GordonOrbiMed Asia Partners IV, L.P.OrbiMed Asia GP IV, L.P.OrbiMed Advisors IV LimitedSunny SharmaSvenH. BorhoWilliam Carter Neild Jonathan T. Silverstein Carl L. GordonOAP(7)40%(8)Lake Bleu Prime Healthcare Master Fund LimitedLakeBleu PrimeLBC Sunshine Healthcare Fund II L.P.LBC SunshineLBC Sunshine202363011,353,491HLake Bleu Prime41.253,763,000HLake Bleu Prime20236 306,699,500H18,052,991H (9)AIHC Master FundAIHC18,270,742HAIHCAIH Capital Group LimitedAIHCapital Group LimitedWeiZhangAIHCapital GroupLimitedWei ZhangAIHC18,270,742H(10)718,282(11)586,597 20236 30XVXV23336 20167 152017224202061720211 18 20236 303,637,05832,733,529H 20231 120236 302,522,813892,529 20236 30 (1)20229 23(i)202412 31(ii)30%202212 3130%202312 3140%202412 31706,1913.6979C+6,348,0912.13C 20233 31(i)202512 31(ii)30%202312 3130%202412 3140%202512 312.13C (2)20208 12.13C (3)20208 12.13C (4)20208 12.13C (5)20223 3HH2022923H8.512023331H11.58 (6)25 (7)(i)H20223 3(ii)11.77 20211 1820231 12023630 20236 302232171,460,030251,3993,077,1184,788,54795,770202212 311,407,8331,455,71920236 304,692,7771.41%25 H 20218 30HH20219 23 H13,000H10.9220236302,724,500HHHHH HH9,972,000H20231120236 30H9,972,